Circulating steroid hormones in prostate carcinogenesis. Part 2: Estrogens

Author(s):  
Jean Fiet ◽  
Frank Giton

AbstractThe aim of this review is to describe the associations between circulating plasma estrogens and prostate cancer (PCa). We recall the origins of estrogens, which derive from the aromatization of androgens, but also by sulfatase hydrolysis of estrone sulfate (E1-S), the main circulating plasma estrogen. We evoke that the carcinogenic effects of estrogens were demonstrated in the rat and murine prostate when estrogens and androgens were simultaneously administered to them. We also describe estrogen proliferative activity and the genotoxicity of estrogen-hydroxylated metabolites with the formation of DNA adducts. We report published aromatase and CYP1B1 polymorphisms found in men with PCa. We published a bibliography on the relation between PCa and prostate inflammation, as well as the possible role of obesity in the aggressiveness of PCa. In this review, we provide an exhaustive list of assays carried out in subjects at high risk for PCa compared with Caucasians, showing that higher estrogen levels were found in the plasma of these subjects at high risk for PCa. Plasma estrone was the estrogen for which plasma concentration was highest in subjects of African descent. We recall the links observed between plasma estrogens, particularly E1-S, and PCa aggressiveness. Finally, we describe assays for determining hydroxylated estrogens and DNA adducts in the urine of men with PCa. We insist on the importance of the technology employed in estrogen measurement and propose the use of mass spectrometry methods to carry out estrogen assays, in order to decrease variability in the results of plasma estrogen assays.

2005 ◽  
Vol 26 (2) ◽  
pp. 171-202 ◽  
Author(s):  
M. J. Reed ◽  
A. Purohit ◽  
L. W. L. Woo ◽  
S. P. Newman ◽  
B. V. L. Potter

Steroid sulfatase (STS) is responsible for the hydrolysis of aryl and alkyl steroid sulfates and therefore has a pivotal role in regulating the formation of biologically active steroids. The enzyme is widely distributed throughout the body, and its action is implicated in physiological processes and pathological conditions. The crystal structure of the enzyme has been resolved, but relatively little is known about what regulates its expression or activity. Research into the control and inhibition of this enzyme has been stimulated by its important role in supporting the growth of hormone-dependent tumors of the breast and prostate. STS is responsible for the hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate to estrone and dehydroepiandrosterone, respectively, both of which can be converted to steroids with estrogenic properties (i.e., estradiol and androstenediol) that can stimulate tumor growth. STS expression is increased in breast tumors and has prognostic significance. The role of STS in supporting tumor growth prompted the development of potent STS inhibitors. Several steroidal and nonsteroidal STS inhibitors are now available, with the irreversible type of inhibitor having a phenol sulfamate ester as its active pharmacophore. One such inhibitor, 667 COUMATE, has now entered a phase I trial in postmenopausal women with breast cancer. The skin is also an important site of STS activity, and deficiency of this enzyme is associated with X-linked ichthyosis. STS may also be involved in regulating part of the immune response and some aspects of cognitive function. The development of potent STS inhibitors will allow investigation of the role of this enzyme in physiological and pathological processes.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 3207-3207 ◽  
Author(s):  
Michael J Thomenius ◽  
Jennifer Totman ◽  
Kat Cosmopoulos ◽  
Dorothy Brach ◽  
Lei Ci ◽  
...  

Abstract t(4;14) chromosome translocations are found in 15% of newly diagnosed multiple myeloma (MM) cases and are associated with high risk. MM cells with t(4;14) over-express the histone methyltransferase (HMT), WHSC1/MMSET/NSD2, which leads to deregulation of gene expression due to increased di-methylation of Histone H3 at lysine 36 (H3K36me2). This activity has been shown to be essential for the survival of t(4;14) MM cells. In addition to WHSC1, another HMT, SETD2, has been shown to methylate H3K36. SETD2 is the only known enzyme capable of tri-methylation of H3K36 and has been reported to play a role in transcriptional elongation and alternative splicing. CRISPR pooled screening has shown that SETD2 activity is required for viability of a variety of cancer cell lines. This led Epizyme to develop small molecule inhibitors of SETD2 enzyme activity in order to understand the role of SETD2 in tumorigenesis. Through our drug discovery efforts, we identified EPZ-040414, a potent and selective inhibitor of SETD2 with low nM cell biochemical activity and broad selectivity against a panel of other HMTs. The proposed role of SETD2 in H3K36 methylation led us to test a panel of MM cells, including 6 t(4;14) cell lines with EPZ-040414. Inhibition of SETD2 resulted in reduced global tri-methylation of H3K36 in t(4;14) bearing MM cell lines. In contrast, there was no effect on global di-methyl H3K36 levels, indicating that WHSC1 activity is not affected by SETD2 inhibition. Moreover, 5/6 t(4;14) MM cell lines showed a cytotoxic response to treatment with EPZ-040414 with IC50s ranging between 60 and 200 nM, while all non-t(4;14) MM cell lines showed limited responses between 1 and 8 μM. Moreover, screening of a 280 cancer cell line panel with a SETD2 inhibitor showed minimal anti-proliferative activity in most cell lines tested. These findings show that t(4;14) MM cell lines require SETD2 activity for survival, suggesting that SETD2 inhibitors are strong candidates for the treatment of this high risk subgroup of MM. Efforts to further understand the interaction between SETD2 and WHSC1 in the molecular pathogenesis of t(4;14) myeloma will be presented. The current chemical series represented by EPZ-040414 is potent, selective, orally available, and currently under further evaluation for its therapeutic potential. Figure. Figure. Disclosures Thomenius: Epizyme Inc.: Employment, Equity Ownership. Totman:Epizyme Inc.: Employment, Equity Ownership. Cosmopoulos:Epizyme Inc.: Employment, Equity Ownership. Brach:Epizyme Inc.: Employment, Equity Ownership. Ci:Epizyme Inc.: Employment, Equity Ownership. Farrow:Epizyme Inc.: Employment, Equity Ownership. Smith:Epizyme Inc.: Employment, Equity Ownership. Chesworth:Epizyme Inc.: Employment, Equity Ownership. Duncan:Epizyme Inc.: Employment, Equity Ownership. Tang:Epizyme Inc.: Employment, Equity Ownership. Riera:Epizyme Inc.: Employment, Equity Ownership. Lampe:Epizyme Inc.: Employment, Equity Ownership.


Diagnostics ◽  
2020 ◽  
Vol 10 (3) ◽  
pp. 126 ◽  
Author(s):  
Sanjeev Shukla ◽  
Janmejai K. Srivastava ◽  
Eswar Shankar ◽  
Rajnee Kanwal ◽  
Akbar Nawab ◽  
...  

The oxidant/antioxidant balance has been implicated in the pathophysiology of prostate cancer. We investigated oxidative damage and antioxidant status in high-risk prostate cancer subjects. Reduced glutathione (GSH) levels were measured in erythrocytes, 8-hydroxydeoxyguanosine (8-OHdG) in leukocytes and plasma levels of catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GSH-R), glutathione S-transferase (GST), superoxide dismutase (SOD), and lipid peroxide products were measured in high-risk and age-matched healthy subjects. Serum PSA levels were significantly higher (p < 0.0001) in high-risk subjects, whereas GST (p < 0.0001) and GSH (p < 0.002) were higher in healthy controls. Levels of 8-OHdG, an oxidized nucleoside of DNA, were significantly increased (p < 0.0001) in high-risk subjects. No marked difference in the levels of CAT (p = 0.237), GSH-Px (p = 0.74), GSH-R (p = 0.344), SOD (p = 0.109), and lipid peroxide products (p = 0129) were observed between two groups. Pearson’s correlation between GST and PSA (r = −0.69 (p < 0.0001)), GST and 8-OHdG (r = −0.62 (p < 0.0004)), GSH and 8-OHdG (r= −0.39 (p = 0.038)), and CAT and GSH-Px (r= −0.33 (p = 0.04)) were found to be negatively correlated, whereas 8-OHdG and PSA were positively associated (r= 0.57 (p < 0.002). These results indicate a significant role of oxidative damage in prostate carcinogenesis, particularly during the early stages of development. In conclusion, our data support the importance of antioxidant defense as a valuable diagnostic and/or prognostic marker in prostate cancer.


GYNECOLOGY ◽  
2014 ◽  
Vol 16 (1) ◽  
pp. 86-92
Author(s):  
I.V. Bakhareva ◽  

Sign in / Sign up

Export Citation Format

Share Document